Now that it has a brand name for the lebrikizumab – Ebglyss – and a recommendation from regulators in Europe, Almirall SA is getting ready to launch the closely watched atopic dermatitis drug imminently and start challenging the market dominance of Sanofi's mega-blockbuster Dupixent.
Key Takeaways
- The EMA has backed lebrikizizumab, which will be marketed as Ebglyss
- An approval in the US for partner Lilly is expected shortly as the firms look to compete with Dupixent
- Limited penetration of
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion on Ebglyss (lebrikizumab) at its September meeting for people with moderate-to-severe atopic dermatitis who are aged 12 and over, weigh at least 40kg and are candidates for systemic therapy